BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
32
Mechanism of Action
Interleukin 4 Receptor alpha Antagonists
Pharmacologic Class:
Interleukin-4 Receptor alpha Antagonist
Indications (12)
older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapiesthose therapies are not advisableolderweighing at least 15 kgeosinophilic esophagitis (EoE)older with chronic spontaneous urticaria (CSU)other forms of urticariaolder with allergic fungal rhinosinusitis (AFRS)Atopic DermatitisAsthmaChronic Obstructive Pulmonary DiseaseCOPD
Clinical Trials (5)
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Started Mar 2026
24 enrolled
Metastatic Colorectal CancerLiver Metastases
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Started Feb 2026
400 enrolled
Chronic Spontaneous Urticaria
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
Started Feb 2026
184 enrolled
Atopic Dermatitis
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Started Jan 2026
150 enrolled
Asthma Control
Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
Started Jan 2026
500 enrolled
Chronic Obstructive Pulmonary Disease COPD